[Sequence treatment of postmenopausal osteoporosis].

Initial therapy for low-risk patients typically involves potent antiresorptive agents such as bisphosphonates or denosumab to reduce bone resorption and fracture risk. For high-risk patients, bone anabolic agents like teriparatide or romosozumab may be preferred to stimulate bone formation, rapidly increase bone mass and enhance fracture prevention. Effective transitions between therapies are essential to sustain skeletal benefits. This review explores evidence-based strategies for sequential osteoporosis treatment.